2015 Sep 15
Nivolumab over docetaxel for patients with NSCLC
Ashish Saxena, M.D., Ph.D., comments on a study that found nivolumab offers better outcomes than docetaxel for patients with advanced squamous-cell non-small cell lung cancer. Read more